ANDROGENETIC ALOPECIA STUDIES
Sanabria et al (starts at 4:40). Prospective cardiovascular evaluation with 24-h Holter and 24-h ambulatory blood pressure monitoring in men using 5 mg oral minoxidil for androgenetic alopecia. J Am Acad Dermatol. 2022 May 18;
Klein E et al (starts at 13:40). Comparing combination low-dose oral minoxidil and topical minoxidil with oral minoxidil alone for the treatment of non-scarring alopecia; a retrospective chart review. J Cosmet Dermatol. 2022 Jun 1.
Cao L et al (starts at 21:19). Nailfold capillaroscopy alterations in androgenetic alopecia: A cross-sectional study. Indian J Dermatol Venereol Leprol. 2022 Feb 28;1-7. doi: 10.25259/IJDVL_714_2021.
Emmanuel Sánchez-Meza et al (starts at 28:17). Microneedling plus topical dutasteride solution for androgenetic alopecia: a randomized placebo-controlled study. J Eur Acad Dermatol Venereol. 2022 Jun 1. doi: 10.1111/jdv.18285. 
David Saceda-Corralo et al. Mesotherapy with Dutasteride in the Treatment of Androgenetic Alopecia. Int J Trichology. 2017 Jul-Sep; 9(3): 143–145.
Liamsombut S et al (starts at 34:45). Sleep quality in men with androgenetic alopecia. Sleep and Breathing. 2022 Apr 25.
 
 
ALOPECIA AREATA STUDIES
Anna Waśkiel-Burnat et al (starts at 41:33). Patients with alopecia areata are at risk of endothelial dysfunction: results of a case-control study. Clin Exp Dermatol. 2022 Mar 31.
Conic et al. Prevalence of cardiac and metabolic diseases among patients with alopecia areata.J Eur Acad Dermatol Venereol . 2021 Feb;35(2):e128-e129.
Youssef S et al (starts at 48:28). Tofacitinib Therapy for Alopecia Areata is not Associated with Adverse Events during COVID-19 Infection. J Am Acad Dermatol. 2022 May 9;S0190-9622(22)00795-2.
McKenzie P et al (starts at 53:32). Evaluation of the Prevalence and Incidence of Pediatric Alopecia Areata Using Electronic Health Record Data. JAMA Dermatol. 2022 May 1;158(5):547-551.